The study drew on two prospective, multicenter Korean registries: the Korea Heart Failure Registry, which enrolled 3,200 patients hospitalized for acute heart failure at 24 tertiary centers between 2004 and 2009, and the Korean Acute Heart Failure Registry, which captured 5,625 patients across 10 tertiary centers between 2011 and 2014. After excluding 442 patients with missing body mass index or diabetes data, the researchers analyzed 8,383 individuals with a mean age of 68.2 years, 52 percent of whom were men. Importantly, the team applied an Asian-specific threshold for overweight, classifying patients as lean if their body mass index fell below 23 kilograms per square meter and overweight if it met or exceeded that value—a cutoff grounded in evidence that cardiometabolic risk rises at lower body weights in Asian populations than in Western ones. Roughly a third of the cohort had diabetes, and the patients were sorted into four groups: overweight non-diabetic, overweight diabetic, lean non-diabetic, and lean diabetic.

The baseline profiles of these groups told a striking story before any outcome data were even examined. Overweight patients without diabetes had the most favorable characteristics: they were younger, less likely to have ischemic heart disease, and displayed lower creatinine, C-reactive protein, and natriuretic peptide levels, along with better echocardiographic measures of cardiac function. At the opposite extreme, lean patients with diabetes carried the heaviest burden of disease, with more advanced heart failure symptoms, greater renal dysfunction, and a higher prevalence of ischemic etiology. That gradient—healthiest at the heavier, non-diabetic end of the spectrum and sickest at the lean, diabetic end—set the stage for outcome differences that were as dramatic as they were consistent.

During the index hospitalization, 5.3 percent of all patients died, with in-hospital mortality peaking at 6.9 percent among lean diabetic patients and falling as low as 4.2 percent among overweight diabetic patients. But it was the post-discharge picture that revealed the paradox in its sharpest form. Over one year of follow-up, 14.9 percent of patients died overall, yet the mortality gradient across the four groups was steep: 9.3 percent among overweight non-diabetic patients, 12.7 percent among overweight diabetic patients, 16.4 percent among lean non-diabetic patients, and a sobering 20.7 percent among lean diabetic patients. Diabetes alone raised the one-year mortality rate from 13.8 to 17.1 percent, but leanness exerted an even larger penalty, lifting mortality from 11.1 to 18.8 percent.

After multivariable adjustment for age, sex, systolic blood pressure, symptom severity, hemoglobin, renal function, ejection fraction, ischemic etiology, and other confounders, the survival advantage of overweight status remained statistically robust for one-year mortality. Overweight diabetic patients faced a 35 percent lower risk of death within a year compared with their lean diabetic counterparts, with an adjusted hazard ratio of 0.65 and a 95 percent confidence interval of 0.53 to 0.79. The same directional benefit appeared among overweight patients without diabetes. Critically, when the researchers tested for an interaction between body mass index and diabetes status, none was found—the protective association held with equal force whether or not a patient had diabetes. When body mass index was modeled as a continuous variable, each single-unit increase was associated with a 7 percent reduction in one-year mortality risk, and restricted cubic spline analysis revealed a smooth, monotonic decline in hazard across the entire observed range of body weight.

Intriguingly, the same pattern did not survive scrutiny for in-hospital mortality. Although the raw death rates favored heavier patients during the admission itself, the association weakened and lost statistical significance once the fully adjusted model accounted for the less favorable baseline profiles of lean patients—including their more advanced heart failure and greater comorbidity burden. This divergence suggests that body mass index carries greater prognostic weight over the months following discharge than during the acute phase, when illness severity and body composition may dominate short-term outcomes more than adiposity itself. In other words, the obesity paradox appears to be primarily a phenomenon of medium-term survival rather than of immediate peri-hospitalization risk.

The research team took considerable care to test whether their findings could be an artifact of statistical fragility. Sensitivity analyses using the World Health Organization overweight cutoff of 25 kilograms per square meter produced nearly identical results, with mortality falling monotonically across body mass index strata from 26.9 percent in the underweight range to just 7.0 percent among those with a body mass index of 30 or higher. Excluding patients with a body mass index below 20—who are most likely to suffer from cardiac cachexia, frailty, or severe malnutrition—did not erase the survival advantage of overweight status, arguing against reverse causality as the sole explanation. Registry-stratified analyses showed consistent associations in both cohorts, with no significant registry-by-body-mass-index interaction, and the pattern held across all three heart failure phenotypes: reduced, mildly reduced, and preserved ejection fraction. Only the smaller mid-range ejection fraction subgroup failed to reach statistical significance, most likely due to insufficient sample size.

Still, the investigators are careful to emphasize the limits of what an observational study can prove. Reverse causality—the idea that leanness reflects advanced disease rather than causing poor outcomes—cannot be dismissed entirely, and the registries lacked longitudinal weight trajectories, body composition data, nutritional markers, and measures of skeletal muscle mass that might distinguish protective adiposity from simply the absence of wasting. The cohort was also exclusively Korean, with a low mean body mass index of 23 kilograms per square meter, raising questions about generalizability to Western populations with very different body composition distributions. HbA1c data were missing in more than three-quarters of patients, diabetes type and duration were not captured, and the cohort predates the widespread use of sodium-glucose cotransporter-2 inhibitors, so the interplay between modern weight-lowering drugs and the paradox remains unresolved. The authors frame their conclusions explicitly as associations, not evidence of a causal protective effect of being overweight.

Yet the clinical implications are difficult to ignore, particularly at a moment when guideline-directed heart failure therapy increasingly includes drugs that cause weight loss. Sodium-glucose cotransporter-2 inhibitors can reduce body weight by 3 to 5 percent, and while trial-level evidence from DAPA-HF and EMPEROR-Reduced suggests these therapies benefit patients across the body mass spectrum without modifying the paradox, the new findings add urgency to the question of whether aggressive weight reduction is appropriate for lean patients with heart failure. Notably, a prespecified analysis of the STEP-HFpEF trial showed that semaglutide improved symptoms and function in overweight patients with preserved ejection fraction in proportion to the weight they lost—hinting that there may be a therapeutic sweet spot, a window of body weight beyond which the prognostic advantage of adiposity diminishes. For now, the message from Korea is unambiguous: among patients hospitalized with heart failure, low body weight—especially when combined with diabetes—identifies a strikingly vulnerable phenotype, and the obesity paradox is no respecter of diabetes status.

Subject of Research: The obesity paradox in heart failure patients with and without diabetes mellitus

Article Title: Obesity paradox in heart failure with and without diabetes mellitus: a retrospective cohort study

Article References: Kwon, O., Yoon, M., & Park, J. J. (2026). Obesity paradox in heart failure with and without diabetes mellitus: a retrospective cohort study. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03007-0

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03007-0

Keywords: obesity paradox, heart failure, diabetes mellitus, body mass index, mortality, KorHF, KorAHF, prognosis, HFrEF, HFpEF, SGLT2 inhibitors, cardiology

Heart valve surgery, a complex intervention often necessitated by degenerative or congenital cardiac conditions, carries significant risk, particularly in older populations. Anticoagulants are prescribed postoperatively to mitigate life-threatening thromboembolic events, a common risk after valvular interventions. However, adherence to these medications can be inconsistent in older adults due to various factors such as polypharmacy, cognitive decline, and socioeconomic barriers. This study distinctly highlights the clinical consequences of non-adherence, presenting a nuanced understanding of the spectrum of complications and healthcare burdens that follow.

Analyzing a robust dataset of elderly valve surgery patients, the researchers employed advanced statistical modeling to evaluate medication adherence patterns over a critical post-discharge period. Non-adherence was rigorously defined not just by missed doses but also by premature discontinuation or inappropriate timing relative to prescribed regimens. These granular insights allowed the research team to correlate specific adherence behaviors with the development of adverse events such as bleeding, stroke, and valve thrombosis.

One of the most striking findings reveals that even moderate lapses in anticoagulant adherence significantly elevate risks for readmission within 30 to 90 days post-surgery. This amplification of vulnerability underscores the fragile balance maintained by anticoagulants in this demographic. The propensity for readmission due to complications not only strains healthcare resources but also profoundly impacts patient quality of life, creating a vicious cycle that challenges traditional care models.

The pathophysiological mechanisms underlying these outcomes are rooted in the delicate equilibrium anticoagulants maintain within hemostatic processes. Valve surgery disrupts endothelial integrity and alters blood flow dynamics, predisposing patients to thrombus formation. Proper anticoagulation prevents fibrin-rich clot development, but inconsistent medication intake interrupts this finely tuned system, rendering patients susceptible to both ischemic and hemorrhagic events. The study compellingly charts these clinical trajectories, enriching existing literature with real-world adherence data.

Importantly, this research also illuminates demographic and psychosocial factors that predict poor adherence. Cognitive impairment, depression, and limited social support emerge as pivotal determinants, suggesting that adherence is not merely a pharmacological issue but an interdisciplinary challenge requiring comprehensive patient-centered strategies. The authors advocate for integrated care models incorporating caregiver education, regular monitoring, and tailored interventions to bolster adherence.

Novel technological solutions also figure prominently in the discussion. Digital adherence tools, such as electronic pill dispensers and mobile health applications, are explored as scalable means to bridge gaps in anticoagulant management. The study’s findings bolster the rationale for embedding such innovations in routine post-discharge care for elderly patients, potentially curbing avoidable complications and enhancing continuity of care across settings.

From a healthcare system perspective, the economic implications of anticoagulant non-adherence are substantial. Increased emergency visits, extended hospital stays, and intensive outpatient monitoring contribute to heightened costs, making adherence a critical target for cost containment efforts. The study provides quantitative estimates of these burdens, underscoring the need for investment in preventive measures to reduce financial strain while improving patient outcomes.

Moreover, the exploration of readmission etiology in this cohort reveals a complex interplay between anticoagulant management and comorbid conditions common in the elderly. Chronic kidney disease, diabetes, and atrial fibrillation co-occur frequently, complicating dosing regimens and risk assessments. This multifactorial risk landscape demands personalized medicine approaches for anticoagulation that balance efficacy and safety tailored to individual patient profiles.

Clinical guidelines currently recommend meticulous monitoring of anticoagulant therapy post valve surgery, yet this study exposes gaps in adherence surveillance and intervention. The authors call for enhanced protocols involving multidisciplinary teams, including pharmacists, nurses, and cardiologists, to ensure adherence is proactively managed. Early identification of at-risk patients through predictive analytics could facilitate timely interventions, reducing adverse events and improving survival rates.

Scientific discourse on anticoagulant adherence has traditionally focused on atrial fibrillation and venous thromboembolism populations, making this study’s valve surgery focus particularly significant. It broadens understanding of specific vulnerabilities in elderly surgical patients, a demographic rapidly expanding with aging populations globally. This work sets a precedent for future prospective studies to validate tailored interventions that could become standard practice.

Furthermore, the study underscores the importance of patient education initiatives, highlighting that knowledge deficits about the critical nature of anticoagulants contribute to non-adherence. Comprehensive discharge planning that integrates clear communication about medication regimens, potential side effects, and signs of complications could empower patients and caregivers alike. Behavioral theories underpinning adherence are discussed, suggesting that multifaceted educational strategies are essential to foster long-term compliance.

Investigating the influence of healthcare accessibility, the research identifies disparities linked to geographic and socioeconomic status. Patients in rural areas or with limited access to specialized cardiology services demonstrate higher non-adherence rates and complication incidences. Bridging such gaps through telemedicine and community health programs emerges as a strategic priority, enabling equitable delivery of anticoagulation care.

The retrospective design of the study, while offering valuable observational insights, also prompts calls for randomized controlled trials to establish causality and evaluate targeted adherence interventions. Nonetheless, the breadth and depth of data analyzed provide a robust foundation for immediate clinical contemplation and policy reform aimed at optimizing anticoagulant use in this vulnerable group.

In conclusion, this pivotal research in geriatric cardiac care articulates a clear narrative: anticoagulant adherence after valve surgery in older adults is a linchpin determinant of outcomes, with widespread implications for patient safety, healthcare utilization, and systemic costs. The authors’ comprehensive approach—integrating clinical, psychosocial, and technological perspectives—sets a new standard for holistic management strategies. As healthcare systems worldwide confront aging populations with complex cardiovascular needs, such evidence-driven insights will be instrumental in designing resilient, patient-centered models of care.

Subject of Research: Anticoagulant adherence and its impact on complications and hospital readmissions in older adults following heart valve surgery

Article Title: Anticoagulant adherence and associated complications and readmissions in older valve surgery adults: insights from a retrospective cohort study

Article References:
Roan, JN., Hu, YS., Chuang, TJ. et al. Anticoagulant adherence and associated complications and readmissions in older valve surgery adults: insights from a retrospective cohort study. BMC Geriatr (2026). https://doi.org/10.1186/s12877-026-07399-6

Image Credits: AI Generated